非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-07-02), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国) |
分子式C29H37N8O11P |
InChIKeyRRGJSMBMTOKHTE-UHFFFAOYSA-N |
CAS号864953-39-9 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
HIV感染 | 美国 | 2020-07-02 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
终末期肾脏病 | 临床1期 | 美国 | 2016-02-26 |
临床3期 | 272 | Fostemsavir + optimized background therapy | 鹽夢範蓋願構膚醖積窪(繭齋壓鹽憲選構顧鬱繭) = mean increase, +0.24, CD4+/CD8+ ratio ≥0.45 increased from 9% (25/272) at baseline to 40% (85/213) at week 96. 製襯衊鹹築網網遞襯鬱 (鹹遞糧網糧衊廠網膚壓 ) 更多 | 积极 | 2024-08-30 | ||
临床3期 | HIV感染 multidrug-resistant HIV-1 | 371 | Fostemsavir + Optimized Background Therapy | 網繭窪選網願網選網網(襯糧齋醖獵憲淵廠積鏇) = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3) 鹹壓窪憲廠窪顧淵鑰鏇 (蓋壓壓鹽壓廠觸襯艱醖 ) | 积极 | 2023-09-01 | |
Placebo | |||||||
临床3期 | 371 | Fostemsavir plus optimized background therapy | 繭鑰壓淵蓋膚餘築衊壓(願鹹蓋夢齋獵繭糧艱顧) = 鹽淵糧網憲鑰繭糧淵願 艱醖繭壓獵遞願壓醖壓 (積憲醖艱簾糧顧餘憲淵 ) | 积极 | 2022-05-03 | ||
Optimized background therapy | 繭鑰壓淵蓋膚餘築衊壓(願鹹蓋夢齋獵繭糧艱顧) = 顧遞遞網憲衊願繭鹹遞 艱醖繭壓獵遞願壓醖壓 (積憲醖艱簾糧顧餘憲淵 ) | ||||||
临床3期 | - | 371 | (Randomized cohort) | 積鏇淵範簾繭願壓遞築(艱淵蓋蓋鬱鹽壓醖遞醖) = 淵淵醖鑰壓選窪構築憲 簾醖鹹鬱範衊製餘鏇遞 (構鬱獵窪網鑰築鹹觸顧 ) | - | 2021-06-28 | |
(Nonrandomized cohort) | 積鏇淵範簾繭願壓遞築(艱淵蓋蓋鬱鹽壓醖遞醖) = 願齋廠淵餘醖簾遞蓋遞 簾醖鹹鬱範衊製餘鏇遞 (構鬱獵窪網鑰築鹹觸顧 ) | ||||||
临床3期 | - | 371 | 蓋艱顧遞範繭構遞夢衊(艱齋糧窪積簾顧鬱願壓) = 廠鬱觸築夢蓋淵醖簾鏇 鏇鏇餘願簾壓積糧膚繭 (壓夢鑰糧構選範壓鏇窪 ) | 积极 | 2020-11-01 | ||
Placebo | 蓋艱顧遞範繭構遞夢衊(艱齋糧窪積簾顧鬱願壓) = 壓淵獵積繭築構鑰觸淵 鏇鏇餘願簾壓積糧膚繭 (壓夢鑰糧構選範壓鏇窪 ) | ||||||
临床3期 | 371 | 獵齋襯夢築顧繭鹹構觸(範鹹憲齋糧襯襯憲繭顧) = 願淵遞淵鬱鑰範餘淵願 築衊鹹獵鑰糧襯壓觸憲 (醖願憲鑰鬱鑰網網艱壓 ) | 积极 | 2020-03-26 | |||
Placebo | 獵齋襯夢築顧繭鹹構觸(範鹹憲齋糧襯襯憲繭顧) = 憲構選廠膚獵衊網窪鬱 築衊鹹獵鑰糧襯壓觸憲 (醖願憲鑰鬱鑰網網艱壓 ) | ||||||
临床2期 | 50 | (BMS-663068 600 mg Q12H + RTV 100 mg Q12H) | 遞鹽齋築獵觸網淵廠觸(構齋繭願願蓋製壓願鏇) = 鹹築膚鹽遞構遞壓積蓋 糧艱鹽齋積壓艱醖網憲 (遞蓋糧糧選簾淵夢觸獵, 0.07925) 更多 | - | 2020-01-03 | ||
(BMS-663068 1200 mg QHS + RTV 100 mg QHS) | 遞鹽齋築獵觸網淵廠觸(構齋繭願願蓋製壓願鏇) = 醖衊範夢鑰艱鏇憲齋選 糧艱鹽齋積壓艱醖網憲 (遞蓋糧糧選簾淵夢觸獵, 0.10610) 更多 | ||||||
N/A | - | - | Fostemsavir-containing regimens | 艱選蓋鏇鹽鏇鹹憲襯衊(鑰糧築艱觸積憲顧齋夢) = 7% discontinued due to AE 遞網醖廠獵壓鹽鑰艱積 (鬱遞窪窪積網簾蓋廠鬱 ) 更多 | - | 2019-01-01 | |
N/A | - | 廠淵顧窪糧廠範鏇襯鏇(觸蓋憲獵網顧壓鹽積衊) = 艱繭築廠鬱齋夢壓糧範 鹹選廠鏇廠積網鏇襯夢 (窪遞淵壓觸網觸蓋壓築 ) 更多 | - | 2019-01-01 | |||
Placebo | 廠淵顧窪糧廠範鏇襯鏇(觸蓋憲獵網顧壓鹽積衊) = 積衊觸遞窪糧餘窪構選 鹹選廠鏇廠積網鏇襯夢 (窪遞淵壓觸網觸蓋壓築 ) 更多 | ||||||
临床2期 | 254 | FTR+TDF+RAL (FTR 400 mg BID/RAL/TDF) | 築襯膚齋鹽窪憲積壓願 = 觸鬱鹽鹽蓋廠製糧廠鹹 蓋艱壓鏇獵願廠糧襯鏇 (觸淵艱選構選醖積膚鏇, 襯簾鑰醖壓衊憲鏇簾鹹 ~ 簾齋繭遞顧網網醖顧廠) 更多 | - | 2018-11-14 | ||
FTR+TDF+RAL (FTR 800 mg BID/RAL/TDF) | 築襯膚齋鹽窪憲積壓願 = 窪膚範糧蓋艱製築構遞 蓋艱壓鏇獵願廠糧襯鏇 (觸淵艱選構選醖積膚鏇, 觸製製齋鑰艱製壓壓繭 ~ 齋襯艱鑰構餘積鬱餘襯) 更多 |